Aroa Biosurgery Ltd

0
ASX:ARX (New Zealand)   Ordinary Shares
A$ 0.72 (-6.49%) Jan 15
At Loss
P/B:
3.03
Market Cap:
A$ 266.36M ($ 165.14M)
Enterprise V:
A$ 252.57M ($ 156.59M)
Volume:
206.70K
Avg Vol (2M):
443.28K
Warning! GuruFocus detected 1 Severe warning sign with ARX. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
206.70K
Market Cap A$:
266.36M
Market Cap $:
165.14M
At Loss
Avg Vol (2M):
443.28K
Enterprise Value A$:
252.57M
Enterprise Value $:
156.59M
PB Ratio:
3.03
Alerts Website Sources Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Aroa Biosurgery Ltd

ISIN : NZARXE0001S1
https://www.aroabio.com
64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Share Class Description:

ASX:ARX: Ordinary Shares
Compare
Compare
ASX:AVRASX:IMRASX:4DXASX:EMVASX:IPDASX:RSHASX:SOMASX:NTIASX:CMPASX:MX1ABTSYKBSXMDTXTER:SHLEWSZSE:300760DXCMXAMS:PHIAZBH
Traded in other countries / regions
ARX.Australia
IPO Date
2020-07-24
Description
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Financial Strength

7/10
Name Current Vs Industry Vs History
Cash-To-Debt 3.18
Equity-to-Asset 0.87
Debt-to-Equity 0.08
Debt-to-EBITDA -3.8
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.16
Distress
Grey
Safe
Beneish M-Score -2.79
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 39.3
3-Year EBITDA Growth Rate 33.4
3-Year EPS without NRI Growth Rate 22
3-Year FCF Growth Rate -23.9
3-Year Book Growth Rate 12.2
Future 3-5Y Total Revenue Growth Rate Estimate 24.32

Momentum Rank

7/10
Name Current Vs Industry Vs History
5-Day RSI 31
9-Day RSI 42.46
14-Day RSI 48.66
6-1 Month Momentum % 6.56
12-1 Month Momentum % -17.72

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.54
Quick Ratio 7.31
Cash Ratio 2.92
Days Inventory 292.36
Days Sales Outstanding 68.02
Days Payable 91.8

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.6
Shareholder Yield % -0.09

Profitability Rank

1/10
Name Current Vs Industry Vs History
Gross Margin % 86.76
Operating Margin % -19.78
Net Margin % -9.84
FCF Margin % -14.09
ROE % -7.92
ROA % -6.84
ROIC % -20.68
3-Year ROIIC % -3.61
ROC (Joel Greenblatt) % -12.11
ROCE % -6.4

GF Value Rank

2/10
Name Current Vs Industry Vs History
Forward PE Ratio 59.23
PS Ratio 3.65
PB Ratio 3.03
Price-to-Tangible-Book 3.79
EV-to-EBIT -42.42
EV-to-Forward-EBIT 42.3
EV-to-EBITDA -151.79
EV-to-Forward-EBITDA 23.86
EV-to-Revenue 3.59
EV-to-Forward-Revenue 2.56
EV-to-FCF -25.85
Price-to-Net-Current-Asset-Value 5.54
Price-to-Net-Cash 36
Earnings Yield (Greenblatt) % -2.36
FCF Yield % -3.72

Financials (Next Earnings Date:2025-01-30 Est.)

ASX:ARX's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Aroa Biosurgery Ltd Executives

Details

GF Value: A$1.84

ASX:ARX

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$) 70.289
EPS (TTM) (A$) -0.02
Beta 1.65
Volatility % 44.76
14-Day RSI 48.66
14-Day ATR (A$) 0.031812
20-Day SMA (A$) 0.735
12-1 Month Momentum % -17.72
52-Week Range (A$) 0.44 - 0.815
Shares Outstanding (Mil) 345.93

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aroa Biosurgery Ltd Filings

Filing Date Document Date Form
No Filing Data

Aroa Biosurgery Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Aroa Biosurgery Ltd Frequently Asked Questions

What is Aroa Biosurgery Ltd(ASX:ARX)'s stock price today?
The current price of ASX:ARX is A$0.72. The 52 week high of ASX:ARX is A$0.82 and 52 week low is A$0.44.
When is next earnings date of Aroa Biosurgery Ltd(ASX:ARX)?
The next earnings date of Aroa Biosurgery Ltd(ASX:ARX) is 2025-01-30 Est..
Does Aroa Biosurgery Ltd(ASX:ARX) pay dividends? If so, how much?
Aroa Biosurgery Ltd(ASX:ARX) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.